Keynote Speakers

Dr. Xiaobing Li, Associate Chief Physician

The Department Of Medical Oncology, Hubei Cancer Hospital, Wuhan, China

Biography: Dr. Xiaobing Li, deputy chief physician and doctor of oncology, is currently a member of the Special Committee for Difficult Tumors of the Chinese Medical Education Association, a member of the Standing Committee for Tumor Prevention and Differentiation of the Medical Science Creation Professional Committee of the Hubei Science Writers Association, and a member of the Standing Committee of the Young Experts Committee of the Hubei Clinical Oncology Society. He is a member of the expert Committee of Immunotherapy (ESCO-IO) of the Hubei Clinical Oncology Society, a member of the Professional Committee of Biological Therapy of the Hubei Immunology Society, and the founder of the tumor science popularization public account "Cancer". He has published a number of SCI papers, obtained a patent for an anti-tumor new drug, and participated in a number of national and provincial projects. His main research interests are tumor immunity and targeted therapy.

Topic: Progress in Clinical Application of Antitumor Angiogenesis Therapy in Advanced Lung Cancer

Abstract: In recent years, anti-tumor angiogenesis therapy, as an emerging therapeutic strategy, has made significant progress in the clinical application of advanced lung cancer. The malignant characteristics of lung cancer are closely related to its high degree of angiogenesis, and inhibiting tumor angiogenesis can effectively prevent tumor growth and metastasis. Currently, several anti-angiogenesis drugs, such as bevacizumab, anlotinib, etc., have been approved for the treatment of advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Studies have shown that combining anti-angiogenic drugs with chemotherapy or immunotherapy can significantly improve the effectiveness of treatment. For example, bevacizumab in combination with chemotherapy has been shown to be more effective than chemotherapy alone and improve patient survival. In addition, research on biomarkers of angiogenesis also provides a basis for individualized treatment and helps to select the most appropriate treatment plan. Although anti-tumor angiogenesis therapy shows great promise in advanced lung cancer, further clinical studies are needed to evaluate its long-term efficacy, side effects, and optimal timing of use. Future development directions include exploring new targets, optimizing combination treatment regimens, and finding biomarkers to predict efficacy, in order to improve the overall prognosis of patients with advanced lung cancer.